The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis.

about

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis

P2860

Q57168071-2D79DDFB-8D71-4059-8C91-84CA532663F9 Q58714854-EAB99664-73FB-4B5C-BA3B-99FE59C92EB8

P2860

The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis.

Item

http://www.wikidata.org/entity/Q51740588

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

The efficacy and safety of ale ...... atic review and meta-analysis.

@en

The efficacy and safety of ale ...... atic review and meta-analysis.

@nl

type

Item

label

The efficacy and safety of ale ...... atic review and meta-analysis.

@en

The efficacy and safety of ale ...... atic review and meta-analysis.

@nl

prefLabel

The efficacy and safety of ale ...... atic review and meta-analysis.

@en

The efficacy and safety of ale ...... atic review and meta-analysis.

@nl

P1476

The efficacy and safety of ale ...... atic review and meta-analysis.

@en

P2093

Danming You

http://www.w3.org/2001/XMLSchema#string

Jian Zhang

http://www.w3.org/2001/XMLSchema#string

Ruolan Qian

http://www.w3.org/2001/XMLSchema#string

Sihan Liu

http://www.w3.org/2001/XMLSchema#string

Xiaoli Zhang

http://www.w3.org/2001/XMLSchema#string

Yuqing Chen

http://www.w3.org/2001/XMLSchema#string

Zengfei Xia

http://www.w3.org/2001/XMLSchema#string

P2860

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Second- and third-generation ALK inhibitors for non-small cell lung cancer

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

High plasma exposure to pemetrexed leads to severe hyponatremia in patients with advanced non small cell lung cancer receiving pemetrexed-platinum doublet chemotherapy.

P304

1105-1115

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S156170

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Peng Luo

Junsheng Fan

P577

2018-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29535535

http://www.w3.org/2001/XMLSchema#string

P932

5840301

http://www.w3.org/2001/XMLSchema#string

The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis.

about

P2860

P2860

The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P932